SPECCRO

CENTRALIZED MPS HUB: UNDER ONE ROOF FOR MULTI‑PLATFORM PRECLINICAL SOLUTIONS.

MPS Landscape: Fragmented Models

MPS providers operate under varied business models: fee-for-service, product-based, and R&D partnerships, making it difficult for sponsors to navigate and deploy platforms efficiently across the preclinical continuum.
Opportunity: Centralized Access

Housing diverse MPS platforms under one roof enables sponsors to match the right technology to the right question, streamlining deployment from early discovery through regulatory-enabling studies.
Operational Strategy

Platform selection should reflect MPS complexity, cost, and operational footprint. A tiered model supports scalable integration and efficient resource allocation.
Regulatory Alignment & Community Trust

Transparent data sharing builds community trust and accelerates regulatory acceptance. Early engagement with global agencies ensures harmonized understanding and broader adoption of NAMs data.

A centralized SPECCRO MPS Hub delivering co-located, multi-platform preclinical solutions that pair the right organ-on-chip technologies with sponsor needs across the preclinical development continuum.

Strategic Alliances

SPECCRO is the architect of drug development execution. We design the roadmap and build co execution partnerships with CROs and leading 2D and MPS providers, all under SPECCRO led design, oversight, and operations. We blend traditional and NAMs approaches with pragmatism, innovation, and regulatory clarity, while integrating diligence on technical outcomes, cost, and speed to keep programs moving with precision and efficiency.

PRANA: Platform for Reproducible Assessment of Non-Animal Alternatives.

Purpose

Deliver a GxP-compliant, quality-assured organ-chip hub that bridges exploratory NAM research with regulatory submissions and drives IP creation for key organ systems.

Vision

Accelerate adoption of human-relevant MPS from exploratory to drug development applications by solving for reproducibility, validation, industry and regulatory acceptance. Develop novel IP for key translatable MPS organ systems.

Key Capabilities

1Centralized, GxP-grade organ-chip hub integrating multi-organ modules for biology, ADME, systemic exposure, metabolite profiling, and target-organ toxicities.

2End-to-end workflows translating exploratory MPS data into IND-ready study packages with integrated QA frameworks.

3IP development for key organ systems to identify translatable NAMs and embed them in regulatory submissions.

4Validation and benchmarking against animal and clinical data to demonstrate predictive value and build confidence.

5Technical enablement through automation, rapid prototyping, and hands-on training to accelerate timelines.

6Modular design balancing high-throughput 2D assays with strategic MPS deployment & curated vendor partnerships.

Capabilities

2D / 3D / MPS / In Vitro

AI / ML / OMICS

Alternative In Vivo Tools

MPS Landscape: Fragmented Models

Opportunity: Centralized Access

Operational Strategy

Regulatory Alignment & Community Trust

Strategic Alliances

SPECCROGRID: Integrating Data for Better Outcomes

Seamlessly integrate diverse preclinical data into a GxP-compliant central hub.

Visualize key metrics and trends through real-time dashboards and sponsor-facing APIs.

Interpret findings with predictive analytics and AI/ML–driven insights.

Monitor and track every study phase with end-to-end reporting tools.

Communicate results via customizable alerts, summaries, and stakeholder portals.

Prepare and manage regulatory submissions using audit-ready, traceable data packages.

Scale co-development of AI/ML models to boost predictive power and operational efficiency.

PRANA: Platform for Reproducible Assessment of Non-Animal Alternatives.

Purpose

Vision

Key Capabilities

Impact